SAN DIEGO, May 13, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended March 31, 2020, and provided an update on its corporate activities and product pipeline. "We are pleased to report that we have recently activated our first clinical trial site for the Phase 3 ReSPECT trial,…

Abstract Book highlights new data from Cidara accepted for presentation at ECCMID 2020 Phase 2 trial shows superiority of rezafungin in time to clear deadly infection Seven abstracts highlight new data on influenza antiviral conjugates (AVCs) from Cloudbreak® antiviral platform SAN DIEGO, May 05, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the publication…

SAN DIEGO, April 28, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two panels discussing antifungal and COVID-19 therapies at the upcoming Infectious Disease Virtual Conference presented by Maxim Group. Presentation Information:Panel:"Antifungals"Date:Tuesday, May 5, 2020Time:12:15 - 1:45 PM ET Panel:"COVID-19 (Therapeutics)"Date:Tuesday, May 5, 2020Time:3:45 - 5:00 PM ET…

SAN DIEGO, April 07, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020. Presentation Information:Date: Tuesday, April 14, 2020Time: 2:50 PM ETWebcast: A live audio webcast and replay of the presentation will be available in the Investors…

SAN DIEGO, March 04, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, reported financial results for the three months and full year ended December 31, 2019, and provided an update on its corporate activities and product pipeline. "2019 was a transformational year for Cidara, as we achieved multiple key corporate and clinical milestones," said Jeffrey Stein, Ph.D., president and chief executive officer…

SAN DIEGO, Feb. 18, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections, today announced that it will present a poster at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR), which takes place from Feb. 19-23, 2020, in…

SAN DIEGO, Feb. 12, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara") today announced the closing of its previously announced rights offering (the "Rights Offering"). At the closing, Cidara sold and issued an aggregate of 6,639,307 shares of its common stock (the "Common Stock") and an aggregate of 531,288 shares of its Series X convertible preferred stock ("Series X Preferred Stock"), pursuant to the exercise of subscription rights in the Rights Offering from its existing…

SAN DIEGO, Jan. 22, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara") today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on January 21, 2020, of Cidara's common stock and Series X convertible preferred stock, and Cidara's warrants issued on May 21, 2018, are entitled to purchase up to 11,952,191…

Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020 $30.0 million to be raised, fully backstopped SAN DIEGO, Jan. 10, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara") today announced its intent to raise $30.0 million through a fully backstopped rights offering. Under the terms of the rights offering, investors as of January 21, 2020 in Cidara's common stock and preferred stock, as well as the…

ASH presentation will include new preclinical data on rezafungin for prevention of PneumocystisSAN DIEGO, Dec. 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present a poster at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, which takes place Dec 7-10, 2019, in Orlando, Fl, and will deliver an oral presentation at the 39th Interdisciplinary Meeting on Anti-Infective Chemotherapy, which…